146 related articles for article (PubMed ID: 33235145)
41. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
[TBL] [Abstract][Full Text] [Related]
42. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
43. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
[TBL] [Abstract][Full Text] [Related]
44. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
Keikhaei B; Yousefi H; Bahadoram M
Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
[TBL] [Abstract][Full Text] [Related]
45. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
[TBL] [Abstract][Full Text] [Related]
46. Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
Ferster A; Tahriri P; Vermylen C; Sturbois G; Corazza F; Fondu P; Devalck C; Dresse MF; Feremans W; Hunninck K; Toppet M; Philippet P; Van Geet C; Sariban E
Blood; 2001 Jun; 97(11):3628-32. PubMed ID: 11369660
[TBL] [Abstract][Full Text] [Related]
47. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.
Oyeku SO; Driscoll MC; Cohen HW; Trachtman R; Pashankar F; Mullen C; Giardina PJ; Velazco N; Racine AD; Green NS
Pediatr Blood Cancer; 2013 Apr; 60(4):653-8. PubMed ID: 23129068
[TBL] [Abstract][Full Text] [Related]
48. Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell Disease.
Pashankar FD; Manwani D; Lee MT; Green NS
J Pediatr Hematol Oncol; 2015 Apr; 37(3):242-3. PubMed ID: 25222060
[No Abstract] [Full Text] [Related]
49. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.
Heitzer AM; Longoria J; Okhomina V; Wang WC; Raches D; Potter B; Jacola LM; Porter J; Schreiber JE; King AA; Kang G; Hankins JS
Br J Haematol; 2021 Oct; 195(2):256-266. PubMed ID: 34272726
[TBL] [Abstract][Full Text] [Related]
50. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
51. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
[TBL] [Abstract][Full Text] [Related]
52. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.
Darbari DS; Nouraie M; Taylor JG; Brugnara C; Castro O; Ballas SK
Eur J Haematol; 2014 Apr; 92(4):341-5. PubMed ID: 24330217
[TBL] [Abstract][Full Text] [Related]
53. Comment on: "Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia".
Dar MS
Pediatr Blood Cancer; 2023 Oct; 70(10):e30532. PubMed ID: 37365772
[No Abstract] [Full Text] [Related]
54. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
Saleh AW; Hillen HF; Duits AJ
Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
[TBL] [Abstract][Full Text] [Related]
55. Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease.
Joseph L; Jean C; Manceau S; Chalas C; Arnaud C; Kamdem A; Pondarré C; Habibi A; Bernaudin F; Allali S; de Montalembert M; Boutonnat-Faucher B; Arlet JB; Koehl B; Cavazzana M; Ribeil JA; Lionnet F; Berthaut I; Brousse V
Blood; 2021 Feb; 137(6):826-829. PubMed ID: 32976551
[TBL] [Abstract][Full Text] [Related]
56. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.
de Montalembert M; Voskaridou E; Oevermann L; Cannas G; Habibi A; Loko G; Joseph L; Colombatti R; Bartolucci P; Brousse V; Galactéros F;
Am J Hematol; 2021 Oct; 96(10):1223-1231. PubMed ID: 34224583
[TBL] [Abstract][Full Text] [Related]
57. Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease.
Fung EB; Barden EM; Kawchak DA; Zemel BS; Ohene-Frempong K; Stallings VA
J Pediatr Hematol Oncol; 2001 Dec; 23(9):604-8. PubMed ID: 11902305
[TBL] [Abstract][Full Text] [Related]
58. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
59. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
60. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
